Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases
Shots:
- 23andMe has out-license its bispecific mAb targeted to block three members of the IL-36 cytokine subfamily & will leverage Almirall’s expertise in medical dermatology & accelerating the development the preclinical program
- Almirall to get exclusive WW rights to develop and commercialize the mAbs and will also be responsible for clinical studies. The focus of the agreement is to strengthen ALmirall’s early-stage research portfolio
- IL-36 is an IL-1 cytokine family targeted for associated with multiple inflammatory diseases- including various dermatological conditions
Click here to read full press release/ article | Ref: Almirall | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com